Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

201438 citationsJournal Articlebronze Open Access

Authors

Yvonne M. Saenger · Clinical Innovations (United States)

Jay Magidson · Icahn School of Medicine at Mount Sinai

Bobby Chi-Hung Liaw · Icahn School of Medicine at Mount Sinai

Ellen de Moll · Icahn School of Medicine at Mount Sinai

Sara Harcharik · Icahn School of Medicine at Mount Sinai

Yichun Fu · Icahn School of Medicine at Mount Sinai

Karl Wassmann

Abstract

Expression levels of CTSD, PLA2G7, TXNRD1, and IRAK3 in peripheral blood are predictive of survival in patients with melanoma treated with tremelimumab. Blood mRNA signatures should be further explored to define patient subsets likely to benefit from immunotherapy.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Melanoma and MAPK Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 20, Issue 12, pp. 3310-3318

DOI: 10.1158/1078-0432.ccr-13-2906

Field-Weighted Citation Impact: 1.64